Recently, we reported a new paradigm for cancer treatment by identifying mechanisms by which endothelin A (ETA) antagonists improve anti-cancer immunity in the body by inhibiting the secretion of tumor-derived sEV and sEV PD-L1 [16,17,18]. The gene discussed is CD274; the disease is neoplasm.